74 PATHWENS I N CSF B Y COMMERCIAL COAGGLUTINATION (CoA) A N D
LATEX AGGLUTINATION (Latex) KITS. U B Schaad, R Kobelt. Dept. Ped., University of Berne, Switzerland.
Rapid detection and identification of pathogens i n bacterial mening i t i s i s essential for prompt i n i t i a t i o n of adequate antimicrobial therapy. Several immunologic techniques have been developed to demons t r a t e bacterial antigens i n CSF. Two commercially available methods have become most popular because they a r e comparatively inexpensive and simple t o perfonn. To assess the value of CoA (Phadebact, Pharmacia: H. influenzae b, H. influenzae a/c/d/e/f, S. pneumoniae, N. men i n g i t i d i s A/B/C/Y/W135) and Latex (Slidex, MQrieux: H. influenzae b, S. pneumoniae, N. meningitidis A , N. meningitidis C), these k i t s were prospectively compared with the standard methods for analyzing CSF specimens from children with suspected meningitis. 206 culture-and stain-negative (Gram and methylene blue) CSF specimens resulted i n specifity of 100 % f o r both types of reagents. With 39 culture-positive CSF specimens from patients before therapy, staining detected 37/39 =95%, CoA 34/39=87%, and Latex 21/39=54%. Cross-reaction with other bacterial antigens was observed i n 7 of these samples by CoA and i n 2 by Latex. With 64 follow-up CSF specimens from patients with bacterial meningitis a f t e r s t a r t of therapy, staining detected 23/64=36%, CoA 32/64:50% (cross-reaction in 13), and Latex 20/64=31% (cross-reaction i n 7 ) . Conclusions: CoA was more sensitive than Latex; however, i n i n i t i a l CSF specimens both k i t s were l e s s sensitive than staining techniques. CoA and Latex were mainly helpful during antibacterial therapy. Cross-reactions were more frequent with CoA (esp. N. meningitidis-test). For routine use these k i t s a r e recommended only a s addition t o standard methpds and never a s rgplacement_of standard methods. 
University,Athens,Greece
As p a r a s i t o l o g y d o e s n o t d e t e c t a l w a y s s u c c e s f u l l y l e i s h m a n i a i n f e c t i o n s , i t was a t t e m p t e d w o r t h t o i n v e s t i g at e t h e p o t e n t i a l u s e o f ELISA f o r d i a g n o s i s o f v i s c e r a l 1 e i s h m a n i a s i s . S p e c i f i c a n t i b o d i e s t o l e i s h m a n i a were s e a r c h e d i n a ) 1 1 0 h e a l t h y c o n t r o l s ( i n f a n t s and c h i l d r e n aged 6 months t o 1 4 y e a r s ) , b ) 8 0 c h i l d r e n c l i n i c a l l y s u s p e c t e d f o r l e i s h m a n i a s i s . None o f t h e normal c h i l d r e n had a n t i l e i s h m a n i a a n t i b o d i e s . I n c o n t r a s t a l l 40 c h i l d r e n w i t h l e i s h m a n i a s i s had a n t i b o d i e s a t t h e t i m e of d i a g n o s i s and 2 , 6 and 1 2 months a f t e r t r e a t m e n t . 1 n 3 1 p a t i e n t s l e i s h m a n i a s were found i n t h e bone marrow smear. I n t h e r e m a i n i n g 9 c h i l d r e n t h e d i a g n o s i s was c o n f i r m e d by immun o f l u o r e s c e n c e t e c h n i q u e , t h e c l i n i c a l c o u r s e and t h e p o s it i v e r e s p o n s e t o s p e c i f i c t r e a t m e n t . T h e p e r s i s t e n c e of h i g h a n t ?he f i r s t c l i n i c a l trial of RIT 4237 rotavirus vaccine indicated t h a t one o r a l vaccination of infants aged 8-11 m t h s w i l l induce 88% protection against rotavirus diarrhoea over an epidenic season of rotavirus ( Vesikari e t a l , Lancet i: 977, 1984) .
i b o d y t i t r e s a t 2 and 6 m o n t h s d i d n o t c o r r e l a t e w i t h t h e s e v e r i t y o r t h e outcome o f t h e d i s e a s e . T h e r e s u l t s d e m o n s t r a t e t h a t ELISA , i s a non i n v
A second p l a c~o n t r o l l e d f i e l d t r i a l involving 347 children aged 6-12 months was s t a r t e d in September 1983. Postvaccination sera were collected £ran 328 children i n Decenber 1983 before the rotavirus epidemic season and t h i r d sera f r a n 291 children i n M3y 1984 a f t e r rotavirus season. A fourth serum w i l l be collected i n 1985.
Before vaccination 90% of t h e children were sermegative f o r rotavirus, and 53% of t h e vaccinees but none of t h e placebo recipients sermonverted by rotavirus ELISA-IgG. During the f i r s t rotavirus season 44% of the seronegative placebo recipients and 63% of the still seronegative vaccinees showed serocmversion indicative of primary rotavirus i n f e c t i m . 'Ibis was associated with c l i n i c a l diarrhoea i n 26 cases (43%) i n t h e placebo recipients and 4 cases (11%) i n the vaccinees (p 0.001). Altogether t h e vaccine protection r a t e f o r rotavirus diarrhoea was 81% i n the f i r s t season.
IXlring the second rotavirus winter epidemic a s of April 15, 1985, 7 cases of rotavirus diarrhoea have been diagnosed in the placebo group and 1 i n the vaccine group ( p r o t e c t i m r a t e 85%). lhese r e s u l t s suggest t h a t the RIT 4237 rotavirus vaccine w i l l induce protection against rotavirus diarrhoea up to the age of 3 years.
EEFECT OF BRFPST-FEEDING CN THE TAKE OF RIT 4237 OPAL 177 rmrav~wsmccm T Vesikari, T Ihluska, A Delen, H Bogaerts, F' E Andre --Department of Clinical Sciences, University of Tampere, Tampere, Finland & Biolcgical Divisim, Smith Kline RIT, Rixensart, Belgium Oral vaccination with a l i v e attenuated bovine rotavirus vaccine s t r a i n RIT 4237 induces cross-protectim against h w rotavirus diarrhoea ( Vesikari e t a l , TUncet i:977, 1984). Oral rotavirus vaccine i s sensitive to g a s t r i c a c i d and should therefore be adminestered with an acid neutralizing substance such a s milk. Vaccination a t the t h of breast feeding would be simple and l c g i c a l in young infants, but breast milk might have antibodies and nonspecific f a c t o r s t h a t prevent the take of the vaccine.
48 breast-fed and 58 bottle-fed (cow's milk o r formula) i n f a n t s aged 6 to 12 months received 108e3 t i s s u e c u l t u r e infective doses of t h e RIT 4237 vaccine imnediately a f t e r feeding. Serum specimens were collected before and 1 month a f t e r vaccination. Seven of t h e b o t t l e f e d but none of t h e breast-fed i n f a n t s had rotavirus IqM antrbody before vaccination. Sercrcmversion by rotavirus ELISA-IgM antibodies was obselved in 36/48 (75%) of the breast-fed and 38/51 (75%) of the bottle-fed infants. The IgG sermonversion r a t e was sanewhat l m e r i n the breast-fed (50%) than i n the bottle-fed (69%) group. Thus in t h i s age grcup breast-feeding d i d not i n h i b i t the vaccine take, but possibly d f i e d the ant* r e s p n s e . Altogether the serological r e s p n s e s were regarded a s satisfactoxy, since it is knam t h a t the c l i n i c a l protection r a t e against rotavirus diarrhoea is b e t t e r than the serological respmse rate. l b e e f f e c t of colostnvn on rotavirus vaccination is now being studied. Connaught Laboratories, Toronto, Canada and swiftwater, PA; USA 22 three months old children received three doses of PRP-D a t 2 months intervals, and 21 only one dose when 7 months old. In both groups half of the children received booster immunization a t 14 months, and the other half a t 18 months. Sera were obtained prior and post immunizations and anti-PRP antibody levels were measured by Farr-type RIA. The vaccine was well tolerated; only mild reactions were noted. The antibody responses t o i n i t i a l immunization have already been published (Lancet, 1985) : The t h i r d dose a t 7 months resulted in high antibody levels, whereas only one dose a t 7 months did not. The geometric mean ( W ) antibody levels before booster immunization a t 14 months were 1.02 ug/ml in children who had received 3 doses o f PRP-0 and 0.22 ugfml when only 1 dose had been given.
The post booster levels (GM) were 40. 41, 43.56, 25.41 and 37.21 ugfml in the four groups. All groups differed significantly from any group of children of the same age immunized with PRP only (GM levels below 1 uglrnl).
In conclusion. A PRP-D booster given a t 14 or 18 months t o chi l 3 e n who were previously immunized a t 3-5-7 or only 7 months was well tolerated and resulted in significantly higher antibody levels than immunization by PRP alone does. This suggests that PRP-0 can induce a real booster e f f e c t . -No complications o r important side e f f e c t s -NO HBV infection -Protective t i t e r s (> 10 mU/ml) i n 76/77 subjects a f t e r 2 doses (63-12400 mU/ml) -1 male "no responder", another male "hyporesponder" t o ShHBVAX doses and no significant increase of HB Ab t i t e r s a f t e r the 4 dose i n both cases -Pr tective t i t e r s in the 32 subjects controlled a t 2 ys. from the 1' ' dose ofhboth vacclnes and possibility of considering optional ths proposed 4 dose of HEVAC B -Sufficient protection of one HBIG dose, 0 , 5 ml/Kg, a t b i r t h i n newborns vaccinated i n the f i r s t days of l i f e .
-Apparent better response t o active irmounisation in passive prophylaxed infants compared with no HBIG treated subjects as observed by Beasley and c o l l .
